Article ISI
LANCET  (2020)

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Cortes, Javier; Cescon, David W.; Rugo, Hope S.; Nowecki, Zbigniew; Im, Seock-Ah; Yusof, Mastura Md; Gallardo, Carlos; Lipatov, Oleg; Barrios, Carlos H.; Holgado, Esther; Iwata, Hiroji; Masuda, Norikazu; Torregroza Otero, Marco; Gokmen, Erhan; Loi, Sherene; et. al.

Abstract

Background Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the addition of pembrolizumab would enhance the antitumour activity of chemotherapy in patients with metastatic triple-negative breast cancer.

Más información

Título según WOS: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Título de la Revista: LANCET
Volumen: 396
Número: 10265
Editorial: Elsevier Science Inc.
Fecha de publicación: 2020
Página de inicio: 1817
Página final: 1828
Notas: ISI